Thank you Henrik. I will now give an update on our European commercializatio, followed by an update on our next steps, including the geographic expansion of Pepaxti to the rest of the world and our pipeline. First, a recap of some of the key investor highlights of our European commercialization. We have a fully approved drug for the treatment of an incurable disease that provides an expanding market opportunity, valued at 1.5 billion SEK. Since our last quarterly update, we have enhanced our efforts in Austria. We have gained access to Spain, adding further potential and diversity to our revenue stream, and we are now fully financed to reach our profitability goal by the end of 2026. To understand the future, Let me remind you briefly of the past. 2023 was the year when we started to gain clinical experience in Germany and entered into a partnership for Greece. We sold at low volumes and saw a positive trend. Quarter by quarter, we achieved nearly 90% growth between the third and fourth quarter. Based on our situation, we had to launch while we were still preparing at the end of the year. We had, however, managed to recruit the full German team. We negotiated the price successfully in Germany. We started to gain clinical experience, raised awareness, as well as initiating some critical activities, such as working to launch a real-world study. Even though Germany is a market that is taking time to unlock, it serves as a good potential and we are confident we will be able to capture that over time. In 2024, we expect an acceleration of European sales by growing in Germany and adding Spain to our revenue stream. The fact that we have managed to agree on a price that reflects our innovation in these two major markets, and that we are managing to attract talent with both experience and network within our field, is creating a solid foundation for this acceleration. When Pepaxti is used, we get the same feedback from all countries. The clinical experience is in general positive, which is continuously strengthening the position for Pepaxti as an important treatment option for late-stage multiple myeloma patients. This may sound obvious, but it is not always the case as many drugs come along with cumbersome administration schedules, a lot of side effects, and reduced quality of life. One of the focus areas of the Multiple Myeloma Congress, which just took place in Paris, was how Pepaxti is positioned by key opinion leaders and how the interest has increased for the full platform of peptide drug conjugates due to the unmet need for capacities, a combination of efficacy, manageable tolerability, and not least, maintained quality of life. There is a similar unmet need in other geographies, which is why we see interest from partners around the world to take on the task. Beyond Europe, we have taken an important step to enter a partnership agreement with a member company of the World Orphan Drug Alliance, Vector Pharma. This partnership will allow us to provide patients in the Middle East and North Africa with Pepaxti on a named-patient sales basis. If we look at the launch sequence in Europe, let me remind you that while we are, of course, working to pull through all four phases, it is the first two launch phases that will contribute to our profitability goal. I will come back to provide a more updated look at where we are in the various countries. The business model for our European case is based on a local approach, with strong support by the headquarters here in Stockholm, and only adding local resources needed without duplicating any efforts at the headquarters and in the countries. In addition, we have a low cost of goods for Pepaxti, which concludes the opportunity for an effective and profitable business. The EBITDA margin on a country level, during peak sales, we estimate about 50%, and we estimate to reach break-even within two years in each country. These are the different steps in the market access process. And as a reminder, the timelines and in particular the review and negotiation phases, are country specific and at large, controlled by payers. If we look at where we are in the various countries, we have added Austria to the countries with healthcare access and have previously been able to sell in Austria. But the inclusion in hospital lists, which we achieved during the first quarter, is now enabling for physicians to prescribe. Due to this important step, we have since April had an MSL working for Oncopeptides focused on Austria. We have also started price negotiations in Norway, and just recently we took the first step in those negotiations by making our first offer for a price. This offer was rejected by the Norwegian payer body. It is common practice for payers to reject the first offer, and this means that we will have to engage in a new round of negotiations before a new decision can be made. While it might seem dramatic sometimes looking at various government summaries of meetings, this is a completely normal part of the market access process, and we commonly do not get a yes, but rather no at first. This doesn't mean that we are ending the process in the country. The negotiation is sometimes only a dialogue between the company and the payer, and sometimes made official, which triggers questions about what we intend to do. And I want to emphasize to all of you that should we decide to move out of the country, we will ensure to communicate that clearly. As for France, we expect to submit the value dossier and initiate the cost-effectiveness benefit review, followed by a discussion in the next few days. Regarding Germany and Greece, we continue to see great progress with continuous positive feedback from the field, and our confidence and focus remain unchanged for these markets. The biggest step taken is, of course, Spain, and I wish to give you a better understanding of where we stand and are heading. We have reached market access in Spain in five months, and to put that into context, the average approval time in Life Sciences in Europe, in Spain reported is 611 days. That is more than 20 months. And our competitors in the same position as us took up to 24 months to conclude. This means that we have achieved national reimbursement in record time, and I think it speaks to the competence of our strategy and our ability to succeed with the concluding price negotiations and market access processes across Europe. To add to that, Pepaxti has been available in Spain for doctors in urgent need of the drug since May 1st, and even though we do not have regional access, we are already seeing the first patient treated just weeks later. While we are glad to see the drug fulfilling this large unmet medical need, and that we can already, through special procedures, help some patients, we expect to see more material sales taking place in the second half of this year, as we are working to achieve regional access. Spain is a market with high potential for Oncopeptides. We have more than 1500 patients in our target population. We can compare this to Germany with a target population of around 2500 patients. There are two important differences to point out between Germany and Spain. Germany is a more scattered market, with thousands of customers prescribing drugs to multiple myeloma patients, compared to hundreds of customers in Spain, which in that sense makes Spain a more centralized market to work with. From the Pepaxti perspective, the great difference is the clinical experience. With more than 100 patients treated in Spain in our clinical development program in 16 sites, having gained experience through our studies. This compared to zero in Germany at launch. I was recently in Spain to meet with the full team and I also met with media. I am proud to see the strong team we managed to recruit, how far they have come already in preparing the launch, and I am truly excited to see the interest from media in our company and drug. Looking forward, we will continue to build out the team with more commercial competence and ensure we continue to build onto the robust clinical experience we already have in Spain. This by real-world data generation and advancing our science in partnership through investigator-initiated trials that are in fact already running. We will, of course, also spend time attending and presenting at congresses, an important way to build further awareness and understanding of Pepaxti among Spanish physicians. The multiple myeloma treatment landscape is rapidly evolving, with different types of immunotherapies being launched. The development of the landscape is confirming the need for a drug like Pepaxti in the later lines. All of our competitors are focused on moving towards earlier lines of treatment and, for example, CAR-T therapies are now already approved in this setting. This is due to better efficacy and tolerability earlier on. This means that late-stage patients, who commonly have an already exhausted immune system, are in need of a different treatment approach. We have the opportunity to take a strong position with capacity. Finally, I want to spend a few minutes on our next-step value drivers. We continue to see China and Japan as our most viable non-EU markets, and we have also added South Korea to our prioritized Asian markets. This is due to the fact that we already have patients studied in South Korea, which we hope can facilitate a shorter regulatory path than in other Asian countries. Looking at the rest of the world opportunities, this map illustrates both the potential in new markets assessed outside of Europe through partnership in yellow, and also our capability to make these opportunities materialize, as we have recently done in the Middle East and North African region. I am looking forward to seeing more countries going yellow and orange on this map as we progress. Having more countries where we sell Pepaxti not only adds revenue, but it also diversifies our revenue stream and makes us even more solid. When we announced the rights issue and explained where we are planning to focus our efforts, we have been very clear that our European commercialization is the focus, but equally clear that we plan to continue progressing our pipeline to ensure that Oncopeptides remains a full biotech company, providing shareholder value both in the present and in the future. Our short-term efforts on advancing our SPiKE platform towards an Investigational New Drug application are going well and continue, and we are currently in the process of selecting a drug candidate. With that, I would like to say thank you to everyone for listening and hand over to the moderator for any questions. If you wish.